{"title":"Response to ‘Why Japan lacks a vibrant biotech industry’","authors":"Hiroka Ashida, John Stanford","doi":"10.1038/s41587-024-02492-w","DOIUrl":null,"url":null,"abstract":"<p>In their April article, Mark Kessel and Chris Vickrey raise several valid concerns about the Japanese life sciences industry and why it is not reaching its full potential<sup>1</sup>. They acknowledge that a negative pricing environment for innovative medicines is part of the problem, as is a history of government underinvestment. Missing from their argument, however, are some recent initiatives from Japanese agencies that aim to address these issues.</p><p>The authors assert that “Japan has simply failed to develop a startup ecosystem, especially in biotech.” However, we argue that the nation’s startup ecosystem is growing. Across all industries, venture capital investments in Japanese startups across all disciplines have increased in the past decade — from US $500 million in 2012 to $9.7 billion in 2023. In biotech specifically, Japanese venture capital investments totaled $913 million in 2023.</p>","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"70 1","pages":""},"PeriodicalIF":33.1000,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1038/s41587-024-02492-w","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
In their April article, Mark Kessel and Chris Vickrey raise several valid concerns about the Japanese life sciences industry and why it is not reaching its full potential1. They acknowledge that a negative pricing environment for innovative medicines is part of the problem, as is a history of government underinvestment. Missing from their argument, however, are some recent initiatives from Japanese agencies that aim to address these issues.
The authors assert that “Japan has simply failed to develop a startup ecosystem, especially in biotech.” However, we argue that the nation’s startup ecosystem is growing. Across all industries, venture capital investments in Japanese startups across all disciplines have increased in the past decade — from US $500 million in 2012 to $9.7 billion in 2023. In biotech specifically, Japanese venture capital investments totaled $913 million in 2023.
期刊介绍：
Nature Biotechnology is a monthly journal that focuses on the science and business of biotechnology. It covers a wide range of topics including technology/methodology advancements in the biological, biomedical, agricultural, and environmental sciences. The journal also explores the commercial, political, ethical, legal, and societal aspects of this research.
The journal serves researchers by providing peer-reviewed research papers in the field of biotechnology. It also serves the business community by delivering news about research developments. This approach ensures that both the scientific and business communities are well-informed and able to stay up-to-date on the latest advancements and opportunities in the field.
Some key areas of interest in which the journal actively seeks research papers include molecular engineering of nucleic acids and proteins, molecular therapy, large-scale biology, computational biology, regenerative medicine, imaging technology, analytical biotechnology, applied immunology, food and agricultural biotechnology, and environmental biotechnology.
In summary, Nature Biotechnology is a comprehensive journal that covers both the scientific and business aspects of biotechnology. It strives to provide researchers with valuable research papers and news while also delivering important scientific advancements to the business community.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
